Carna Biosciences, Inc.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Carna Biosciences, Inc. made a loss over the last year. Carna Biosciences, Inc. owes ¥1.23 for every ¥1 it owns. Carna Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Dec 2025.
P/E ratio
LossCarna Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-18.10Carna Biosciences, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
¥7.4 BThe total market value of all of Carna Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeCarna Biosciences, Inc.'s net worth is negative (¥408 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-438.7%Carna Biosciences, Inc. lost 438.7% of its shareholders' money over the last year, lower than almost all Healthcare companies in Japan.
Owes vs Owns
1.23×Carna Biosciences, Inc. owes ¥1.23 for every ¥1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in Japan.
Dividend yield
NoneCarna Biosciences, Inc. does not currently pay a dividend.
Revenue growth
-9%Revenue fell 9% in the year to Dec 2025, and shrank 25% a year on average over 3 years.
Profit growth
LossCarna Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-375.0%Carna Biosciences, Inc. lost ¥375 for every ¥100 of revenue.
Interest cover
Not coveredCarna Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtCarna Biosciences, Inc. had ¥198 M more debt than cash (net debt) at Dec 2025.
Questions
What is Carna Biosciences, Inc.'s return on equity?
Carna Biosciences, Inc. lost 438.7% of its shareholders' money over the last year, lower than almost all Healthcare companies in Japan.
How much does Carna Biosciences, Inc. owe compared with what it owns?
Carna Biosciences, Inc. owes ¥1.23 for every ¥1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in Japan.
Does Carna Biosciences, Inc. pay a dividend?
No. Carna Biosciences, Inc. does not currently pay a dividend.
Is Carna Biosciences, Inc.'s revenue growing?
Revenue fell 9% in the year to Dec 2025, and shrank 25% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.